info@seagull-health.com
SeagullHealth
语言:
search
new
What Are the Side Effects of Almotriptan (Almogran)?
503
Article source: Seagull Pharmacy
Nov 10, 2025

Almotriptan (Almogran) is a 5-HT1B/1D receptor agonist (a triptan-class drug), widely used for the acute treatment of migraine in adults and adolescents aged 12 years and older. As a potent prescription medication, its clinical use must strictly comply with medication guidelines.

What Are the Side Effects of Almotriptan (Almogran)?

Common Side Effects

Digestive system: Nausea (2%), dry mouth (1%).

Nervous system: Paresthesia (e.g., tingling, burning sensation) (1%).

Adolescent patients (12-17 years old): Common reactions include dizziness (3-4%), drowsiness (5%), headache (1-2%), and vomiting (2%).

Severe Side Effects Requiring High Alert for Almotriptan (Almogran)

Cardiovascular System Risks

It may induce myocardial ischemia, myocardial infarction, or even life-threatening arrhythmias; some cases occur in patients without underlying heart disease.

If symptoms such as chest pain, a feeling of throat tightness, jaw pain, or difficulty breathing occur after medication administration, seek medical attention immediately.

Cerebrovascular Accidents

Rare but severe cerebral hemorrhage, subarachnoid hemorrhage, or stroke, which are particularly likely to be mistaken for migraine symptoms and lead to delayed treatment.

Peripheral vascular ischemic reactions: Such as Raynaud's syndrome, ischemic enteropathy (manifested as abdominal pain, bloody diarrhea).

Serotonin Syndrome

When used in combination with SSRI/SNRI antidepressants, life-threatening serotonin syndrome may occur.

Typical symptoms include: Mental abnormalities (agitation, hallucinations).

Autonomic disorders (tachycardia, blood pressure fluctuations).

Gastrointestinal symptoms: Nausea, vomiting, diarrhea.

Precautions for Almotriptan (Almogran) Use

Contraindication Screening

It is contraindicated in patients with ischemic heart disease, a history of cerebrovascular disease, or uncontrolled hypertension.

Dosage Adjustment for Special Populations

Patients with hepatic/renal impairment: The starting dose is 6.25 mg, and the maximum dose within 24 hours should not exceed 12.5 mg.

Medication Timing Control

It should only be used when a migraine attack is clearly confirmed; other triptan-class drugs or ergotamine-class drugs are prohibited within 24 hours.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Recommended Articles
Precautions for Using Almotriptan (Almogran)
Almotriptan (Almogran) is a selective serotonin 1B/1D receptor agonist and an important drug in the clinical acute treatment of migraine attacks. As a triptan-class medication, there are many key aspe...
How to Use Almogran (Almotriptan)
Almogran (Almotriptan) belongs to the triptan class of drugs. It is mainly used for the acute treatment of migraine with or without aura in adults, as well as the acute treatment of migraine headaches...
Indications for Almogran (Almotriptan)
Almogran (Almotriptan) is a selective serotonin receptor agonist belonging to the triptan class of drugs, specifically indicated for the acute treatment of migraine attacks.Indications for Almogran (A...
How to Purchase Almogran (Almotriptan)
Almogran (Almotriptan) is a prescription medication used for the acute treatment of migraine headaches, belonging to the triptan class of drugs. Due to its effectiveness, many patients seek informatio...
How to Purchase Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder)
Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder) is a triple-combination therapy consisting of fluticasone furoate, umeclidinium bromide, and v...
How to Use Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder)
Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder) is a fixed-dose combination inhaler containing three active pharmaceutical ingredients: flutic...
Precautions for Using Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder)
Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder) is a fixed-dose combination preparation containing three active ingredients: fluticasone furoa...
What Are the Side Effects of Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder)?
Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder) is a triple-combination therapy medication containing fluticasone furoate (an inhaled corticos...
Related Articles
Dosage and Administration, Recommended Dose of Elacestrant (Orserdu)
Elacestrant (Orserdu) is a selective estrogen receptor degrader (SERD), which provides an important treatment option for patients with estrogen receptor-positive, HER2-negative advanced or metastatic ...
What Are the Indications for Elacestrant (Orserdu)?
Elacestrant (Orserdu) is a novel endocrine therapy agent that demonstrates significant value in the treatment of advanced breast cancer with specific gene mutations. As an estrogen receptor antagonist...
What Are the Purchase Channels for Elacestrant (Orserdu)?
With the advancement of medical technology, elacestrant (Orserdu), a targeted drug for breast cancer with specific gene mutations, has brought new treatment options for patients. As the first oral sel...
Adverse Reactions of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor indicated for the treatment of patients with advanced non-small cell lung cancer harboring MET gene mutations. By precisely inhibiting the act...
What are the Precautions for Capmatinib (Tabrecta) Administration?
Capmatinib (Tabrecta) is a targeted therapy drug for MET gene mutations, demonstrating significant efficacy in the treatment of advanced malignancies such as non-small cell lung cancer.What are the Pr...
Dosage and Administration, Recommended Dosage of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor, offering a precision treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation...
What Are the Indications for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a targeted therapy medication that plays an important role in the treatment of non-small cell lung cancer associated with specific gene mutations. As a MET kinase inhibitor, i...
What Are the Purchase Channels for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a highly selective MET inhibitor that has demonstrated significant efficacy in patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutat...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved